Ka Li Pharmaceutical: Controlling shareholders make a voluntary commitment to a sales ban.

Songli Pharmaceuticals announced on the Hong Kong Stock Exchange that the company's board of directors hereby declares that, to express their firm confidence in the long-term value and future prospects of the company, Dr. Wu Jinzi has voluntarily committed that, together, they will not sell any shares of the company held directly or indirectly by them or entities controlled by them before the release of the following three clinical data.